Here are the 10-K annual reports from VivoSim Labs, Inc. (VIVS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow VIVS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VIVS filings page.
VivoSim Labs, Inc. is repositioning as a pharmaceutical and biotechnology services company, providing toxicology testing of drugs and candidates in 3D human liver and intestine tissue models using its NAMkind platform. At a scientific conference, the liver platform showed 87.5% sensitivity and 100% specificity on challenging liver‑toxicity cases.
The company previously focused on FXR314 for inflammatory bowel disease but sold its FXR program to Eli Lilly in March 2025 for $10.0 million upfront, including $1.0 million in escrow, plus up to $50.0 million in potential milestones; a $5.0 million development milestone was received in July 2026. VivoSim reports a broad IP portfolio with 39 issued U.S. patents and more than 50 issued international patents.
Financially, as of March 31, 2026, current assets were about $6.6 million and current liabilities $2.8 million, for working capital of $3.8 million. The company recorded a $11.5 million operating loss for 2026 and an accumulated deficit of $356.0 million. Management and the auditor highlight substantial doubt about its ability to continue as a going concern without additional capital. Non‑affiliate equity was valued at $7,538,844 as of September 30, 2025, and there were 3,494,071 shares outstanding on July 10, 2026.